NuPotential is pioneering the discovery and development of next generation “Epi-drugs”, novel compounds that modulate epigenetic targets and their processes, initially for the treatment of cancer. Epigenetics is the study of the epigenome, a group of functionally relevant and ubiquitous genomic modifications that do not involve a change in sequence in the underlying genome’s DNA sequence. With its role as a key player of gene expression, epigenetics is a rapidly emerging and highly promising source of new drug targets.

NuPotential discovery technologies and efforts focus on the two major components of the epigenetic machinery: histone modification and DNA methylation. Many serious disease states, including cancer, diabetes and neurodegenerative disorders are linked to or are a result of aberrant gene expression regulated by the epigenome. The Company’s two most advanced programs include histone methyltransferase and DNA methyltransferase modulators initially being evaluated as cancer treatments. Research at NuPotential and by others has shown these select areas hold great promise as attractive and tractable therapeutic targets.